RNA Aptamer Targeting CEA Linkage Region for Metastasis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and inhibiting cancer metastasis, particularly involving the Carcinoembryonic antigen (CEA), face challenges in specificity and effectiveness due to limitations with antibodies, such as immunogenicity and stability issues.
Innovation Solution
Development of a novel RNA molecule specifically binding to the linkage region between the N domain and A1 domain of CEA, acting as an RNA aptamer, which is highly specific, stable, and non-immunogenic, and can be modified for enhanced in vivo availability and resistance to RNase, thereby inhibiting and diagnosing metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are used to target CEA for cancer diagnosis and metastasis inhibition, then binding specificity to CEA can be achieved, but immunogenicity and stability issues arise
Solution Approach 1:
The patent uses RNA aptamers as synthetic copies that mimic the binding function of antibodies against CEA. These RNA molecules are selected through SELEX to specifically bind CEA with high affinity, providing the same diagnostic and therapeutic functionality as antibodies without triggering immune responses or suffering from stability issues. The RNA aptamers serve as artificial substitutes that replicate the essential binding capability while eliminating the harmful side effects of antibody-based approaches.
2Reliability
If RNA aptamer is designed to bind CEA linkage region, then specificity and non-immunogenicity are improved, but resistance to RNase degradation must be enhanced
Solution Approach 1:
The patent employs chemical modifications of the RNA aptamer structure to change its physical and chemical parameters, specifically enhancing resistance to RNase degradation. Modifications may include 2'-O-methyl, phosphorothioate, or locked nucleic acid (LNA) substitutions at strategic positions within the RNA sequence. These parameter changes maintain the aptamer's ability to specifically bind CEA while providing protection against enzymatic degradation in biological systems, thereby improving stability without compromising specificity or immunogenicity profile.
3Reliability
If RNA aptamer is administered in vivo, then cancer metastasis inhibition can be achieved, but pharmacokinetic properties must be optimized
Solution Approach 1:
The patent develops composite structures by conjugating the RNA aptamer with carrier molecules such as cholesterol, polyethylene glycol (PEG), or lipids. These composite constructions improve the pharmacokinetic properties of the RNA aptamer by enhancing cellular uptake, increasing circulation half-life, and improving tissue distribution. The carrier molecules form a protective complex with the aptamer, allowing it to reach target CEA-expressing cells more effectively while maintaining its metastasis inhibition efficacy. This composite approach addresses pharmacokinetic limitations without compromising the core therapeutic function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA aptamer effectively inhibits cancer metastasis by specifically targeting CEA-expressing cells, reducing liver metastasis in animal models, and provides a stable, non-immunogenic means for diagnosing CEA-related cancers with improved pharmacokinetic properties.
Implementation Method 1
RNA aptamer specifically binding to a linkage region between N domain and A1 domain of CEA
Data Source
AI summary
Provided are RNA aptamer specifically binding to cancer metastasis-inducing domain of CEA (Carcinoembryonic antigen), a composition for prevention and/or inhibition and/or diagnosis of cancer metastasis containing the same as an active ingredient, and a method of prevention and/or inhibition and/or diagnosis of cancer metastasis using the same.